Source link : https://www.newshealth.biz/health-news/another-kras-inhibitor-scores-an-early-win-in-advanced-non-small-cell-lung-cancer/
A China-developed KRAS inhibitor led to objective responses in half of patients with previously treated KRAS-mutant non-small cell lung cancer (NSCLC), a prospective non-randomized trial showed. Overall, 61 of 123 patients responded to garsorasib as confirmed by an independent review committee (IRC), and the median duration of response (DOR) exceeded a year. An additional 39% […]
Author : News Health
Publish date : 2024-06-11 21:21:11
Copyright for syndicated content belongs to the linked Source.